Health & Fitness
Fri, January 27, 2012
HYDERABAD, India--([ BUSINESS WIRE ])--Dr. Reddyas Laboratories (NYSE: RDY) wishes to clarify that the media reports highlighting its troubles with the US health authorities related to certain promotional material for Fondaparinux Sodium are misleading .
Dr. Reddyas had received a communication from the Division of Professional Promotion (DPP), US FDA directing for changes related to certain promotional material for Fondaparinux Sodium for Injection. The company has already addressed all matters raised by the DPP, US FDA in the letter issued on January 10, 2012. The DPP informed Dr. Reddy's Laboratories on January 24, 2012 that the matters are now considered closed.
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr. Reddyas
Dr. Reddyas Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products a" Dr. Reddyas offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetes, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: [ www.drreddys.com ]